NEUROCRINE BIOSCIENCES INC
For the period ended Mar 31, 2025. Filed May 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 5, 2025
NBIX$169.14+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months EndedMarch 31, | ||
|---|---|---|
| (in millions) | 2025 | 2024 |
| Cash flows from operating activities: | ||
| Net income | $7.9 | $43.4 |
| Adjustments to reconcile net income to net cash from operating activities: | ||
| Stock-based compensation expense | 52.8 | 44.5 |
| Charges associated with convertible senior notes | — | 88.7 |
| Depreciation | 6.6 | 5.3 |
| Accretion of discount on available-for-sale debt securities, net | (4.6) | (7.1) |
| Amortization of intangible assets | 1.0 | 0.9 |
| Changes in fair values of equity investments | 30.6 | (1.6) |
| Deferred income taxes | (13.7) | (15.6) |
| Other | 7.9 | 3.4 |
| Change in operating assets and liabilities: | ||
| Accounts receivable | (36.9) | (11.3) |
| Inventory | (1.7) | 1.1 |
| Accounts payable and accrued liabilities | 12.4 | (18.6) |
| Other assets and liabilities, net | 2.5 | (2.8) |
| Cash flows from operating activities | 64.8 | 130.3 |
| Cash flows from investing activities: | ||
| Purchases of available-for-sale debt securities | (273.2) | (320.1) |
| Sales and maturities of available-for-sale debt securities | 298.1 | 276.3 |
| Capital expenditures | (10.7) | (11.2) |
| Cash flows from investing activities | 14.2 | (55.0) |
| Cash flows from financing activities: | ||
| Issuances of common stock under benefit plans | 32.1 | 69.9 |
| Repurchases of common stock | (150.0) | — |
| Cash flows from financing activities | (117.9) | 69.9 |
| Change in cash, cash equivalents and restricted cash | (38.9) | 145.2 |
| Cash, cash equivalents and restricted cash at beginning of period | 241.0 | 259.1 |
| Cash, cash equivalents and restricted cash at end of period | $202.1 | $404.3 |
| Supplemental disclosures: | ||
| Accrued capital expenditures | $2.7 | $1.1 |
| Cash paid for income taxes | $0.6 | $0.2 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.